from Reuters: Science News https://reut.rs/2VkTJnZ
//
Alphabet's GV leads funding in gene editing company Verve Therapeutics
May 08, 2019 / / in Reuters: Science News / with No comments /
GV, Alphabet Inc's venture capital arm, led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
from Reuters: Science News https://reut.rs/2VkTJnZ
//
from Reuters: Science News https://reut.rs/2VkTJnZ
//
Related Posts:
Brazil seeks China's OK for genetically modified sugarcane- SpaceX postpones satellite launch in Florida due to high winds
- Trump seeks extra $1.6 billion in NASA spending to return to moon by 2024
- In crisis-hit Argentina, cancer researcher turns to game show for funds
- Quakes show that moon, gradually shrinking, is tectonically active
0 comments:
Post a Comment